HC Wainwright Analysts Decrease Earnings Estimates for VRCA

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) – Equities researchers at HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for shares of Verrica Pharmaceuticals in a report released on Tuesday, April 8th. HC Wainwright analyst O. Livnat now anticipates that the company will post earnings of ($0.09) per share for the quarter, down from their previous forecast of ($0.08). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Verrica Pharmaceuticals’ current full-year earnings is ($1.46) per share. HC Wainwright also issued estimates for Verrica Pharmaceuticals’ Q3 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.32) EPS, FY2026 earnings at ($0.17) EPS and FY2027 earnings at ($0.02) EPS.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. The company had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $1.30 million. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%.

Separately, Needham & Company LLC reissued a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $9.50.

Verrica Pharmaceuticals Trading Down 4.4 %

Shares of VRCA stock opened at $0.44 on Thursday. The company has a market capitalization of $40.62 million, a price-to-earnings ratio of -0.24 and a beta of 1.68. The firm has a 50-day moving average price of $0.60 and a 200 day moving average price of $0.87. Verrica Pharmaceuticals has a twelve month low of $0.38 and a twelve month high of $11.41.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Several large investors have recently added to or reduced their stakes in VRCA. Caligan Partners LP acquired a new position in shares of Verrica Pharmaceuticals during the 4th quarter valued at about $5,201,000. Boothbay Fund Management LLC purchased a new stake in Verrica Pharmaceuticals in the fourth quarter valued at approximately $1,811,000. State Street Corp increased its position in Verrica Pharmaceuticals by 13.5% during the third quarter. State Street Corp now owns 512,821 shares of the company’s stock worth $744,000 after purchasing an additional 61,041 shares during the last quarter. Geode Capital Management LLC raised its stake in Verrica Pharmaceuticals by 4.8% during the fourth quarter. Geode Capital Management LLC now owns 477,269 shares of the company’s stock worth $334,000 after purchasing an additional 21,789 shares during the period. Finally, Sovran Advisors LLC acquired a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at $267,000. 42.45% of the stock is currently owned by hedge funds and other institutional investors.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.